More than 400 clinical research professionals answered the same fundamental question in 2025: where does AI actually stand in trial operations, and where is it falling short? The result is the WCG CenterWatch 2025 AI Benchmarking Report, released this month, and its value is less in confirming enthusiasm for AI than in giving sponsors, CROs, and sites something they have not had before: a shared baseline against which to measure their own progress or stagnation.
The industry’s appetite for AI is not in question. What remains genuinely murky is whether that appetite translates into operational discipline. Survey respondents span all three major stakeholder categories, which matters because AI adoption at a large sponsor bears almost no resemblance to adoption at a community research site with a three-person staff. Collapsing those realities into a single headline number would be misleading; a report that separates them by role and organization type gives trial teams a far more honest mirror. The benchmark framing is deliberate: organizations can identify not just where the industry is trending, but where they specifically sit relative to peers doing similar work.
The regulatory backdrop adds urgency. The FDA issued draft guidance in January 2025 establishing a risk-based credibility framework for AI and machine learning models used to support regulatory decision-making, signaling that the agency expects sponsors to demonstrate, not just assert, that their AI tools are fit for purpose. That shift puts a premium on exactly the kind of documented, benchmarked adoption evidence this report attempts to capture. Separately, published data on AI-enabled clinical activity shows average implementation costs running near $1.1 million per activity, rising to $3.2 million for data quality and cleaning solutions. Those figures reframe AI adoption as a capital allocation decision, not a technology enthusiasm exercise.
The single marker worth tracking after this report is how sites, specifically the smaller and mid-tier research sites that struggle most with AI readiness, begin to use these benchmarks in contract and partnership conversations with sponsors. If site qualification processes start incorporating AI capability assessments tied to this kind of industry-wide data, the report’s influence will be measurable and durable rather than decorative.
Source link: https://cms.centerwatch.com/insights/wcg-centerwatch-2025-ai-benchmarking-report/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
